- Home
- PHUN vs SNTI Comparison
PHUN vs SNTI Comparison
Compare PHUN & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- SNTI
- Stock Information
- Founded
- PHUN 2009
- SNTI 2016
- Country
- PHUN United States
- SNTI United States
- Employees
- PHUN N/A
- SNTI N/A
- Industry
- PHUN EDP Services
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- PHUN Technology
- SNTI Health Care
- Exchange
- PHUN Nasdaq
- SNTI Nasdaq
- Market Cap
- PHUN 55.9M
- SNTI 53.6M
- IPO Year
- PHUN N/A
- SNTI N/A
- Fundamental
- Price
- PHUN $2.36
- SNTI $1.96
- Analyst Decision
- PHUN Buy
- SNTI Strong Buy
- Analyst Count
- PHUN 2
- SNTI 3
- Target Price
- PHUN $7.75
- SNTI $9.67
- AVG Volume (30 Days)
- PHUN 192.6K
- SNTI 274.5K
- Earning Date
- PHUN 11-06-2025
- SNTI 11-12-2025
- Dividend Yield
- PHUN N/A
- SNTI N/A
- EPS Growth
- PHUN N/A
- SNTI N/A
- EPS
- PHUN N/A
- SNTI N/A
- Revenue
- PHUN $2,357,000.00
- SNTI N/A
- Revenue This Year
- PHUN N/A
- SNTI N/A
- Revenue Next Year
- PHUN $72.40
- SNTI $150.00
- P/E Ratio
- PHUN N/A
- SNTI N/A
- Revenue Growth
- PHUN N/A
- SNTI N/A
- 52 Week Low
- PHUN $2.21
- SNTI $1.26
- 52 Week High
- PHUN $6.29
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- PHUN 38.33
- SNTI 47.15
- Support Level
- PHUN $2.21
- SNTI $1.80
- Resistance Level
- PHUN $2.40
- SNTI $1.98
- Average True Range (ATR)
- PHUN 0.11
- SNTI 0.15
- MACD
- PHUN -0.03
- SNTI -0.05
- Stochastic Oscillator
- PHUN 19.05
- SNTI 10.20
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.